|
Molecular properties generated using the CDK |
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes (source: FDA (1955)) |
IUPAC Name ![]() |
| 2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 796 | hydroxychloroquine |
Synonyms ![]() |
| Dolquine® |
| Plaquenil® |
Database Links ![]() |
|
| CAS Registry No. | 118-42-3 |
| ChEMBL Ligand | CHEMBL1535 |
| DrugBank Ligand | DB01611 |
| PubChem CID | 3652 |
| Search Google for chemical match using the InChIKey | XXSMGPRMXLTPCZ-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | XXSMGPRMXLTPCZ |
| Search PubMed clinical trials | hydroxychloroquine |
| Search PubMed titles | hydroxychloroquine |
| Search PubMed titles/abstracts | hydroxychloroquine |
| Wikipedia | Hydroxychloroquine |
| Comments |
| Although this drug has direct effects on survival of the malaria parasite it also appears to be an antagonist of two of the human TOLL-like receptors (TLR7 and TLR9). Antagonism of these receptors is likely related to the anti-inflammatory action of this drug in some auto-immune diseases. |